Our broad pipeline is initially focused on delivering oral macrocycle candidates against targets validated by blockbuster biologic drugs. The goal is to provide oral alternatives that provide meaningful value to healthcare and will enable the treatment of many more patients. In addition, we are exploring a broader variety of therapeutic areas with attractive target classes, including both intra- and extracellular targets.